+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030- Product Image
Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030- Product Image
New

Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 6040935
Description Jump to:
The Immunotherapy Drugs Market was valued at USD 257.60 Billion in 2024, and is projected to reach USD 486.36 Billion by 2030, rising at a CAGR of 11.20%. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights

  • The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
  • The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
  • The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
  • The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
  • This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Immunotherapy Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of The suppliers
3.4.1.2. Bargaining power of The buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape.
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis
4.1. Drug Type Market Share, 2024 & 2030
4.2. Drug Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Monoclonal Antibodies
4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Immunomodulator
4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Vaccine
4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis
5.1. Indication Market Share, 2024 & 2030
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
5.4. Cancer
5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.6. Infectious Diseases
5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Australia
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Amgen Inc.
7.5.1.1. Participant’s Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Recent Developments/ Strategic Initiatives
7.5.2. Novartis AG
7.5.2.1. Participant’s Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Recent Developments/ Strategic Initiatives
7.5.3. AbbVie Inc.
7.5.3.1. Participant’s Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Recent Developments/ Strategic Initiatives
7.5.4. Pfizer Inc.
7.5.4.1. Participant’s Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Recent Developments/ Strategic Initiatives
7.5.5. F. Hoffmann-La Roche Ltd
7.5.5.1. Participant’s Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Recent Developments/ Strategic Initiatives
7.5.6. Johnson & Johnson Services, Inc.
7.5.6.1. Participant’s Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Recent Developments/ Strategic Initiatives
7.5.7. AstraZeneca
7.5.7.1. Participant’s Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Recent Developments/ Strategic Initiatives
7.5.8. GSK plc.
7.5.8.1. Participant’s Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Recent Developments/ Strategic Initiatives
7.5.9. Sanofi
7.5.9.1. Participant’s Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Recent Developments/ Strategic Initiatives
7.5.10. Bayer AG
7.5.10.1. Participant’s Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Immunotherapy Drugs Market, by Region, 2018-2030 (USD Million)
Table 4. Global Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 5. North America Immunotherapy Drugs Market, by Country, 2018-2030 (USD Million)
Table 6. North America Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 7. U.S. Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 8. Canada Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 9. Mexico Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 10. Europe Immunotherapy Drugs Market, by Country, 2018-2030 (USD Million)
Table 11. Europe Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 12. Germany Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 13. UK Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 14. France Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 15. Italy Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 16. Spain Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 17. Sweden Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 18. Denmark Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 19. Norway Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 20. Asia Pacific Immunotherapy Drugs Market, by Country, 2018-2030 (USD Million)
Table 21. Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 22. China Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 23. Japan Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 24. India Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 25. South Korea Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 26. Australia Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 27. Thailand Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 28. Latin America Immunotherapy Drugs Market, by Country, 2018-2030 (USD Million)
Table 29. Latin America Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 30. Brazil Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 31. Argentina Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 32. Middle East & Africa Immunotherapy Drugs Market, by Country, 2018-2030 (USD Million)
Table 33. Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 34. South Africa Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 35. Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 36. UAE Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
Table 37. Kuwait Immunotherapy Drugs Market, by Drug Type, 2018-2030 (USD Million)
List of Figures
Figure 1 Immunotherapy drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Segment outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Immunotherapy drugs market dynamics
Figure 12 Immunotherapy drugs market: Porter’s five forces analysis
Figure 13 Immunotherapy drugs market: PESTLE analysis
Figure 14 Immunotherapy drugs market: Drug type segment dashboard
Figure 15 Immunotherapy drugs market: Drug type market share analysis, 2024 & 2030
Figure 16 Monoclonal antibodies market, 2018-2030 (USD Million)
Figure 17 Immunomodulator market, 2018-2030 (USD Million)
Figure 18 Vaccine market, 2018-2030 (USD Million)
Figure 19 Immunotherapy drugs market: Indication segment dashboard
Figure 20 Immunotherapy drugs market: Indication market share analysis, 2024 & 2030
Figure 21 Cancer market, 2018-2030 (USD Million)
Figure 22 Autoimmune diseases market, 2018-2030 (USD Million)
Figure 23 Infectious diseases market, 2018-2030 (USD Million)
Figure 24 Others market, 2018-2030 (USD Million)
Figure 25 Immunotherapy drugs market revenue, by region
Figure 26 Regional marketplace: Key takeaways
Figure 27 North America immunotherapy drugs market, 2018-2030 (USD Million)
Figure 28 U.S. country dynamics
Figure 29 U.S. immunotherapy drugs market, 2018-2030 (USD Million)
Figure 30 Canada country dynamics
Figure 31 Canada immunotherapy drugs market, 2018-2030 (USD Million)
Figure 32 Mexico country dynamics
Figure 33 Mexico immunotherapy drugs market, 2018-2030 (USD Million)
Figure 34 Europe immunotherapy drugs market, 2018-2030 (USD Million)
Figure 35 UK country dynamics
Figure 36 UK immunotherapy drugs market, 2018-2030 (USD Million)
Figure 37 Germany country dynamics
Figure 38 Germany immunotherapy drugs market, 2018-2030 (USD Million)
Figure 39 France country dynamics
Figure 40 France immunotherapy drugs market, 2018-2030 (USD Million)
Figure 41 Italy country dynamics
Figure 42 Italy immunotherapy drugs market, 2018-2030 (USD Million)
Figure 43 Spain country dynamics
Figure 44 Spain immunotherapy drugs market, 2018-2030 (USD Million)
Figure 45 Denmark country dynamics
Figure 46 Denmark immunotherapy drugs market, 2018-2030 (USD Million)
Figure 47 Sweden country dynamics
Figure 48 Sweden immunotherapy drugs market, 2018-2030 (USD Million)
Figure 49 Norway country dynamics
Figure 50 Norway immunotherapy drugs market, 2018-2030 (USD Million)
Figure 51 Asia Pacific immunotherapy drugs market, 2018-2030 (USD Million)
Figure 52 Japan country dynamics
Figure 53 Japan immunotherapy drugs market, 2018-2030 (USD Million)
Figure 54 China country dynamics
Figure 55 China immunotherapy drugs market, 2018-2030 (USD Million)
Figure 56 India country dynamics
Figure 57 India immunotherapy drugs market, 2018-2030 (USD Million)
Figure 58 Thailand country dynamics
Figure 59 Thailand immunotherapy drugs market, 2018-2030 (USD Million)
Figure 60 South Korea country dynamics
Figure 61 South Korea immunotherapy drugs market, 2018-2030 (USD Million)
Figure 62 Australia country dynamics
Figure 63 Australia immunotherapy drugs market, 2018-2030 (USD Million)
Figure 64 Latin America immunotherapy drugs market, 2018-2030 (USD Million)
Figure 65 Brazil country dynamics
Figure 66 Brazil immunotherapy drugs market, 2018-2030 (USD Million)
Figure 67 Argentina country dynamics
Figure 68 Argentina immunotherapy drugs market, 2018-2030 (USD Million
Figure 69 MEA immunotherapy drugs market, 2018-2030 (USD Million)
Figure 70 South Africa country dynamics
Figure 71 South Africa immunotherapy drugs market, 2018-2030 (USD Million)
Figure 72 Saudi Arabia country dynamics
Figure 73 Saudi Arabia immunotherapy drugs market, 2018-2030 (USD Million)
Figure 74 UAE country dynamics
Figure 75 UAE immunotherapy drugs market, 2018-2030 (USD Million)
Figure 76 Kuwait country dynamics
Figure 77 Kuwait immunotherapy drugs market, 2018-2030 (USD Million)
Figure 78 Company categorization
Figure 79 Company market position analysis
Figure 80 Strategic framework

Companies Mentioned

The companies profiled in this Immunotherapy Drugs market report include:
  • Amgen Inc.
  • Novartis AG
  • AbbVie Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • GSK plc.
  • Sanofi
  • Bayer AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 257.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 486.36 Billion
Compound Annual Growth Rate11.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immunotherapy Drugs Market by Type, Application, End-User - Global Forecast 2025-2030 - Product Image

Immunotherapy Drugs Market by Type, Application, End-User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Cancer Immunotherapy Drugs Market by Type, Indication, End-user - Global Forecast 2025-2030 - Product Image

Cancer Immunotherapy Drugs Market by Type, Indication, End-user - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 209 Pages
  • Global
From
Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030 - Product Image

Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030

  • Report
  • 110 Pages
  • Global
From
Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user - Product Image

Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user

  • Report
  • 118 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.